BioCryst Pharmaceuticals stock
BCRXNASDAQBioCryst Pharmaceuticals, Inc., HealthcareISIN US09058V1035
37Score 37 out of 100, Weak
Price and trend
39 / 100
Price history
+7.0% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 13% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 51).
The price is 31% below its 52-week high. Largest decline in 20 years: 93% (September 2007 to November 2008).
Chart figures for advanced users
- SMA 50$8.28
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$8.80
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)51
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$6.24
- The lowest closing price of the last twelve months.
- Resistance$11.11
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- BioCryst Pharmaceuticals, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $1.98B, is number 133 of 296 companies in its industry on MEQIRI.
- MEQIRI Score 37 out of 100 (Weak): rank 592 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 117.9% a year since 2020, Biotechnology median 19.7%.Growth 70
- High return on capitalReturn on invested capital 98.4% in fiscal 2025, Biotechnology median −24.3%.
Weaknesses
- DilutionShare count up 25% since 2020.Capital allocation 18
- Loss-makingLoss of $359.66M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 48% a year over the last 12 months.Stability 57
Its standout strength is growth, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
A fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at more than four times the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 60.3% on the twelve months before. Revenue has grown strongly since 2006, at around 30% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 98%, operating 39%, net 30%. Last 12 months: net −37%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 4 Nov 2026EPS reported $0.14 (expected $0.09)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 3.5% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$2.290.0%
- Revenue
- $710.08M0.0%
- Earnings per share
- $0.56−3.5%
- Revenue
- $742.66M−0.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +3.1%Total revenue guidance raised to $690 million to $715 million, ORLADEYO guidance of $625 million to $645 million maintained, operating cost guidance lowered to $420 million to $440 million.
“Given closing of the navenibart EU license, we are raising our total revenue guidance to the range of $690 million to $715 million. Despite the delay in the pediatric launch, we feel long-term ORLADEYO trends are intact and hence, maintaining our full year 2026 ORLADEYO revenue guidance of $625 million to $645 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $696,535 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at BioCryst Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 37
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Aurinia PharmaceuticalsAUPH $2.17B69
- First Tracks BiotherapeuticsTRAX $2.12B47
- ZymeworksZYME $2.02B63
- Harmony Biosciences HoldingsHRMY $2.01B73
- Agios PharmaceuticalsAGIO $1.96B40
- Zenas BioPharmaZBIO $1.95B38
- Fortrea HoldingsFTRE $1.93B41
- Kailera TherapeuticsKLRA $1.87B41
ETFs that hold BioCryst Pharmaceuticals
Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 2.05% | 0.49% | €26.29M |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.19% | 0.30% | €185.82M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.19% | 0.40% | €1.49B |
Show 5 more
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.13% | 0.35% | €1.21B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.06% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.05% | 0.30% | €4.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.03% | 0.43% | €2.48B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.02% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 11 Sep 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.